Edition:
United Kingdom

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

8.40CAD
13 Dec 2018
Change (% chg)

$-0.11 (-1.29%)
Prev Close
$8.51
Open
$8.50
Day's High
$8.55
Day's Low
$8.31
Volume
88,335
Avg. Vol
189,764
52-wk High
$14.75
52-wk Low
$6.65

Latest Key Developments (Source: Significant Developments)

Trogarzo Phase III Data Analysis Presented At HIV Drug Therapy Glasgow 2018
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Theratechnologies Inc ::TROGARZO® PHASE III DATA ANALYSIS PRESENTED AT HIV DRUG THERAPY GLASGOW 2018: PATIENTS NOT ACHIEVING PRIMARY ENDPOINT AT DAY 7 EXPERIENCED CLINICAL BENEFIT BY END OF STUDY.THERATECHNOLOGIES INC - OF 40 PATIENTS ENROLLED IN PHASE III CLINICAL TRIAL, ONLY SEVEN DID NOT ACHIEVE PRIMARY ENDPOINT..THERATECHNOLOGIES INC - PATIENTS IN THE STUDY WHO DID NOT ACHIEVE PRIMARY ENDPOINT EVENTUALLY DID EXPERIENCE CLINICAL BENEFITS DURING STUDY..  Full Article

Theratechnologies Reports Q3 Earnings Per Share C$0.00
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018.Q3 EARNINGS PER SHARE C$0.00.Q3 REVENUE C$17.71 MILLION VERSUS I/B/E/S VIEW C$16.8 MILLION.Q3 EARNINGS PER SHARE VIEW C$-0.01 -- THOMSON REUTERS I/B/E/S.  Full Article

Theratechnologies Q3 Loss Per Share C$0.04
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018.Q3 LOSS PER SHARE C$0.04.Q3 REVENUE C$17.71 MILLION VERSUS I/B/E/S VIEW C$16.8 MILLION.Q3 EARNINGS PER SHARE VIEW C$-0.01 -- THOMSON REUTERS I/B/E/S.  Full Article

Theratechnologies Q2 Loss Per Share C$0.03
Thursday, 5 Jul 2018 

July 5 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 SALES ROSE 23.1 PERCENT TO C$12.3 MILLION.Q2 LOSS PER SHARE C$0.03.  Full Article

Theratechnologies Submits Novel Single-Vial Formulation Of Egrifta For FDA Approval
Wednesday, 4 Jul 2018 

July 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES SUBMITS NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA® (TESAMORELIN FOR INJECTION) FOR FDA APPROVAL.THERATECHNOLOGIES INC - FILED SUPPLEMENTAL NEW DRUG APPLICATION WITH FDA FOR A SINGLE-VIAL FORMULATION OF EGRIFTA.  Full Article

Theratechnologies Announces US$50 Mln Bought Deal Offering Of Certain Notes
Wednesday, 30 May 2018 

May 30 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES US$50 MILLION BOUGHT DEAL OFFERING OF 5.75% CONVERTIBLE UNSECURED SENIOR NOTES.THERATECHNOLOGIES - INTENDS TO USE PROCEEDS OF OFFERING TO FUND PAYMENTS DUE UNDER AMENDMENT OF EMD SERONO TERMINATION AGREEMENT.  Full Article

FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA
Tuesday, 1 May 2018 

May 1 (Reuters) - Theratechnologies Inc ::FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION).THERATECHNOLOGIES - FDA DETERMINED LARGE-SCALE POST-APPROVAL TRIALS NO LONGER REQUIRED AS CURRENT LABELING ADEQUATELY REFLECTS SAFETY PROFILE OF EGRIFTA.THERATECHNOLOGIES - FOR YEAR ENDED NOV 30, 2017, CO ESTIMATED POST-APPROVAL COMMITMENTS WILL REQUIRE $13 MILLION INVESTMENT, WHICH WILL NO LONGER BE NEEDED.  Full Article

Theratechnologies Reports Q1 Loss Per Share C$0.04
Thursday, 5 Apr 2018 

April 5 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF 2018.THERATECHNOLOGIES INC <<>> Q1 REVENUE C$10.22 MLN VS I/B/E/S VIEW C$10.7 MLN.THERATECHNOLOGIES INC <<>> Q1 SHR LOSS C$0.04.THERATECHNOLOGIES - AS AT FEB 28, CASH, BONDS AND MONEY MARKET FUNDS AMOUNTED TO $32.5 MLN COMPARED TO $32.9 MLN AT END OF PREVIOUS FISCAL YEAR.  Full Article

Theratechnologies Announces FDA Approval Of Trogarzo (Ibalizumab-Uiyk) Injection
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH THERAPY, TROGARZO™ (IBALIZUMAB-UIYK) INJECTION, THE FIRST HIV-1 INHIBITOR AND LONG-ACTING MONOCLONAL ANTIBODY FOR MULTIDRUG RESISTANT HIV-1.  Full Article

Theratechnologies announces new data from the pivotal phase III trial of Ibalizumab
Wednesday, 15 Feb 2017 

Theratechnologies Inc : Theratechnologies announces new data from the pivotal phase III trial of HIV monoclonal antibody and long-acting investigational antiretroviral Ibalizumab . Theratechnologies - patients enrolled in phase III trial experienced significant decrease in viral load after receiving single loading dose of Ibalizumab 2,000 mg . Says no notable trends in laboratory abnormalities were observed. .Says safety results in this phase III trial are consistent with ones previously observed in phase IIB trial..  Full Article

CANADA STOCKS-TSX futures point to higher open

June 20 Futures for Canada's main stock index were higher on Wednesday after ending down in the previous session, led by a drag in the energy sector on Tuesday.